The global coxsackievirus infections treatment market is currently valued at USD 5.5 Billion in 2023 and is anticipated to expand at a CAGR of 8.2%. Owing to the technological advances in healthcare the market is likely to propel to USD 12.1 Billion by 2033.
An increase in demand for improved healthcare infrastructure and an increasing incidence rate is likely to drive the growth of the coxsackievirus infections treatment market in the forecast period.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 5.5 Billion |
| Projected Forecast Value (2033) | USD 12.1 Billion |
| Global Growth Rate (2023 to 2033) | 8.2% CAGR |
Coxsackieviruses are non-enveloped viruses belonging to the picornaviridae family and enterovirus genus that possess linear single-stranded RNA as their genetic material. Based on their pathogenicity tested on mice, these are categorized into group A and group B viruses.
Group A viruses are known to cause skin and mucous membrane infections, leading to disorders such as herpangina, hand-foot-and-mouth (HFM) disease, and acute hemorrhagic conjunctivitis (AHC).
Group B viruses infect the pancreas, liver, and heart, leading to various conditions such as pericarditis, hepatitis, myocarditis, and pleurodynia. According to Centers for Disease Control and Prevention (CDC) estimates, coxsackievirus infections accounted for around 25% of the neonatal enterovirus infections reported from 1983 to 2003. People from all age groups get infected by coxsackievirus; however, children are more susceptible to the infection. Fetuses or newborns are at a high risk of infection if their mother gets infected during pregnancy. These viruses are found in the feces, fluid in blisters, nasal secretions, and saliva of an infected patients.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
Growing Incidences of Infections Cause by Coxsackievirus to Drive the Market Growth
Major factors driving the global coxsackievirus diagnostics market are an increase in the incidence of coxsackievirus infections, the surge in awareness among the people, and rigorous government initiatives to reduce the incidence of these infections.
Also, the increasing awareness regarding hand, foot, and mouth disease treatment among people, the availability of cost-effective drugs in the market, and the high prevalence of viral infection causing HFMD in children across the globe is expected to be the key factor driving the growth of coxsackievirus infections treatment market.
Increasing investments in research and development activities to drive the market growth
The global coxsackievirus infections treatment market is anticipated to observe impressive growth during the forecast period, 2023 to 2033. Extensive research and development are propelling the growth of the market, globally.
The other factors supporting the market’s growth are, the increasing government investments in research & development activities, the growing footprint of pharmaceutical manufacturers, developed healthcare infrastructure, rising awareness among the masses, and technological advancements.
Also, ease in FDA approvals for hand, foot, and mouth disease (HFMD) drugs in the clinical trial phase is further projected to drive the growth of the coxsackievirus infections treatment market. Owing to the large patient pool due to HFMD, the demand for coxsackievirus infections treatment is upsurging.
Lack of Awareness Regarding Coxsackievirus to Restrain the Market Growth
One of the major factors hindering the growth of the coxsackievirus infections treatment market over the analysis period includes the lack of awareness regarding the infection. The high cost of therapeutics is another factor that is expected to impede the market growth.
Lack of resources and accessibility in remote areas is one of the key factors likely to hamper the growth of the coxsackievirus infections treatment market. Moreover, the development of more sensitive, efficient, and yet simple rapid diagnostic systems that can be applied to direct and indirect diagnosis remains a challenge in the coxsackievirus infections treatment market.
Advancement in Healthcare to Boost the Market Growth in Region
The market in the North American region is anticipated to observe vibrant growth during the forecast period 2023 to 2033. This can be attributed to the growing developments in the healthcare sector as a result of rising research and development activities in this industry. The region is expected to hold the highest CAGR of 8.0% during the forecast period.
North America led the market in terms of revenue due to the presence of several leading players in the region and various strategic initiatives undertaken by them. Moreover, various government initiatives to promote the diagnosis of various infectious diseases are likely to offer lucrative growth opportunities during the coming years.
For instance, in February 2012, CDC received reports of 63 persons with signs and symptoms of HFMD or with fever and atypical rash in Alabama (38 cases), California (seven), Connecticut (one), and Nevada (17). Coxsackievirus A6 (CVA6) was detected in 25 (74%) of those 34 patients by reverse transcriptase–polymerase chain reaction and partial sequencing of the VP1 gene at the CDC or at the California Department of Public Health.
Increasing Prevalence of HFMD in The Region to Boost the Market Growth
The Asia Pacific's coxsackievirus infection treatment market is expected to rise at a CAGR of 7.9% from 2023 to 2033. Asia Pacific dominates the coxsackievirus infection treatment market owing to the high geriatric population and increasing disease burden in economies such as India, China, and South Korea.
Asia Pacific is projected to hold the largest shares in the global coxsackievirus infection treatment market primarily due to the growing prevalence of HFMD in children in the Asia Pacific region coupled with Asia Pacific being the most vulnerable area for a number of outbreaks of EV71 HFMD.
The growing healthcare industry and an aging population consequently would lead to an increased patient population in these countries. India, China, and Brazil are expected to be rapidly growing markets, owing to an increase in investments by governments in order to enhance healthcare facilities.
| United Kingdom | 8.0% |
|---|---|
| India | 7.9% |
| South Korea | 7.5% |
| China | 7.6% |
| United States of America | 8.1% |
Acetaminophen Segment to Generate Significantly High Revenue
On the basis of drug type coxsackievirus infection treatment market is classified into acetaminophen, paracetamol, and ibuprofen. Among these acetaminophen registers the highest demand in the coxsackievirus infections treatment market owing to the fewer side effects registered with the usage of this drug as compared to others. coxsackievirus infections treatment was found major used in the management of blisters in the mouth and rashes on hands and feet.
The rising prevalence of viral infections in children below age 10 and the growing economic burden caused by HFMD is one of the major factors driving the demand for coxsackievirus infections treatment drugs for the early management of viral infection in children, thereby fueling the market growth over the globe. The Acetaminophen segment held a dominant market share in the year 2023 and is estimated to grow with the fastest CAGR rate of 8.0% over the forecast period 2022 to 2023.
Hospital Pharmacy Segment Remains Dominant Among Other Types
The hospital pharmacy segment dominated the global market in 2023 with a revenue share of over 55.0%. The growth of the segment is attributed to the increasing prevalence of coxsackievirus infections and hospitalization for treatment.
Hospital pharmacies preserve the stock of products related to coxsackievirus infections for out-patients as well as in-patients. The segment will be driven further by growing consumer awareness and increased investments in healthcare infrastructure in developing and underdeveloped countries.
The online pharmacies segment is expected to be the fastest-growing distribution channel segment. This growth can be attributed to user-friendly interfaces and convenience offered by these pharmacies, in terms of access, prices, and delivery. In addition, they have several discounts on purchases of a certain amount or offer bundle pricing for many products.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
With technological innovations happening at a rapid pace, and companies looking for ways to increase customer engagement, start-ups are taking all possible steps to establish a name for themselves in the coxsackievirus infections treatment market.
Some of the start-ups in the coxsackievirus infections treatment market include-
Some of the key players present in the global coxsackievirus infections treatment markets are Adimmune Corp., CJ HealthCare Corp., Takeda Pharmaceutical Co Ltd., Shanghai Zerun Biotechnology Co Ltd., Chongqing Zhifei Biological Products Co Ltd., Johnson & Johnson Consumer Inc., GlaxoSmithKline plc., Emergex Vaccines Holdings Ltd, CJ HealthCare Corp., Thermo Fisher Scientific Inc., and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, applications, and industries.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR 8.2% from 2023 to 2033 |
| Expected Market Value (2023) | USD 5.5 Billion |
| Projected Forecast Value (2033) | USD 12.1 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion & CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends & Pricing Analysis |
| Segments Covered | Drug Type, Route of Administration, Distribution Channel, Regions |
| Regions Covered | Compass Minerals International, Inc.; DPL-USA; NuGenTec; Plant-Prod Inc.; ProChem, Inc.; SAE Manufacturing Specialties Corp; SOPerior Fertilizer Corp.; Tessenderlo Kerley, Inc.; The Mosaic Company; Ebrator Biochemicals Inc.; Haviland Enterprises, Inc.; Interpid Potash, Inc.; Jost Chemical Co.; Lifeasible; Noah Chemicals |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, Australia, New Zealand, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Adimmune Corp.; CJ HealthCare Corp.; Takeda Pharmaceutical Co Ltd.; Shanghai Zerun Biotechnology Co Ltd.; Chongqing Zhifei Biological Products Co Ltd.; Johnson & Johnson Consumer Inc.; GlaxoSmithKline plc.; Emergex Vaccines Holdings Ltd; CJ HealthCare Corp.; Thermo Fisher Scientific Inc. |
| Customization | Available Upon Request |
In 2023, the overall market is estimated to generate a revenue of nearly USD 5.5 billion.
The automotive waste segment accounts for over 50% of the global market demand.
The region is expected to grow at 7.9% CAGR through 2033.
The regional market could witness 8.1% CAGR through 2033.
Adimmune, CJ Healthcare, and Takeda are known to be the leading market players.
| Estimated Size, 2025 | USD 8,125.2 million |
|---|---|
| Projected Size, 2035 | USD 11,890.2 million |
| CAGR (2025 to 2035) | 3.9% |
| Market Size (2023) | USD 1.31 Billion |
|---|---|
| Projected Market Value (2033) | USD 1.76 Billion |
| Market CAGR (2023 to 2033) | 3.0% |
| Expected Market Value (2023) | USD 638.3 Million |
|---|---|
| Anticipated Forecast Value (2033) | USD 1,260 Million |
| Projected Growth Rate (2023 to 2033) | 7.04% CAGR |
Explore Therapy Area Insights
View Reports
Coxsackievirus Infections Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
